Inspection Report

Riverdale Nursing Home: Medication Monitoring Failure NY

September 4, 2025

Bronx, NY

351 views

BRONX, NY - A state inspection at Riverdale Nursing Home revealed serious lapses in medication monitoring, with staff failing to obtain required blood tests for a resident receiving high doses of an anticonvulsant medication despite multiple reminders from pharmacy consultants.

Critical Medication Monitoring Failure Puts Resident at Risk

The facility's breakdown in basic medication safety protocols centered on Resident #39, diagnosed with Non-Alzheimer's Dementia and Schizoaffective Disorder. This resident was receiving 625 milligrams of Depakote three times daily - a substantial dose totaling 1,875 milligrams per day of this powerful anticonvulsant medication.

Despite the facility's own policies requiring physicians to "address laboratory and other diagnostic test results in a timely manner based on the resident's condition and the clinical significance of the results," staff failed to follow through on critical blood monitoring for this medication. The inspection found that although a pharmacy consultant specifically recommended obtaining serum levels on February 11, 2025, noting they were "unable to locate a recent serum level in the chart," the test was never performed.

The Nurse Practitioner documented agreement with the pharmacist's recommendation on February 12, 2025, stating "Agree Will do" and ordered the blood test for February 13. However, no evidence existed that the serum level was ever drawn, and neither the physician nor nurse practitioner followed up on the missing results.

Medical Risks of Unmonitored Depakote Administration

Depakote (valproic acid) requires careful monitoring through regular blood tests because therapeutic and toxic levels exist within a narrow range. Without proper monitoring, residents face significant health risks including liver damage, pancreatitis, and blood disorders. The medication can also cause excessive sedation, tremors, and cognitive impairment when levels become too high - particularly concerning for a resident already diagnosed with dementia.

Standard medical protocol dictates that Depakote levels should be checked within two weeks of starting the medication, then regularly thereafter - typically every six months for stable patients. The monitoring becomes even more critical when administering higher doses like the 1,875 milligrams daily this resident was receiving. Blood tests help determine whether the medication remains within the therapeutic range of 50-100 micrograms per milliliter, preventing both ineffective treatment and dangerous toxicity.

Systematic Communication Breakdown

The inspection revealed a troubling lack of accountability in the facility's medication management system. When interviewed on March 19, 2025, the Nurse Practitioner stated they "wait for the Registered Nurse to inform them of the laboratory test results" and claimed they were "not notified of the results or the reason why was the serum level not obtained."

This passive approach to critical medication monitoring directly contradicted the facility's own policies, which explicitly state that physicians must periodically review all medications and monitor for possible adverse drug reactions. The Medical Director, when interviewed the same day, acknowledged that "the Nurse Practitioner should have followed up timely when they had not received the laboratory results."

The facility's Laboratory and Diagnostic Test Results policy, revised in January 2025, clearly outlined responsibilities for processing test requisitions and reporting results. It specifically noted that concerns about test result handling "should not prevent timely, clinically appropriate management of a current result or clinical situation." Yet in this case, the absence of any follow-up mechanism allowed a critical safety test to fall through the cracks entirely.

Industry Standards and Best Practices Ignored

Professional standards in long-term care require robust systems for tracking laboratory orders and results, particularly for high-risk medications. Facilities typically employ multiple safeguards including electronic tracking systems, paper logs, and designated staff responsible for following up on pending tests. The complete absence of follow-up for over a month after ordering the Depakote level represents a fundamental failure in these basic safety systems.

For residents with cognitive impairment who cannot advocate for themselves, these monitoring protocols become even more essential. The resident's moderate cognitive impairment and psychiatric conditions meant they likely could not recognize or report symptoms of medication toxicity, making regular blood monitoring the primary method for ensuring their safety.

The pharmacy consultant's role in identifying the missing serum level demonstrates the importance of regular medication reviews. However, the facility's failure to act on this expert recommendation - despite documented agreement from the Nurse Practitioner - highlights a concerning gap between policy and practice that left a vulnerable resident at unnecessary risk for over a month without proper medication monitoring.

Full Inspection Report

The details above represent a summary of key findings. View the complete inspection report for Riverdale Nursing Home from 2025-03-19 including all violations, facility responses, and corrective action plans.

Additional Resources

Editorial Standards

Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).

Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.

Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.

Last verified: June 20, 2026 · Our methodology

Quick Answer

NEW RIVERDALE REHAB AND NURSING in BRONX, NY was cited for violations during a health inspection on March 19, 2025.

However, **no evidence existed that the serum level was ever drawn**, and neither the physician nor nurse practitioner followed up on the missing results.

Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.

Frequently Asked Questions

What happened at NEW RIVERDALE REHAB AND NURSING?

However, **no evidence existed that the serum level was ever drawn**, and neither the physician nor nurse practitioner followed up on the missing results.

How serious are these violations?

Violation severity varies from minor documentation issues to serious safety concerns. Review the inspection report for specific deficiency codes and scope. All violations must be corrected within required timeframes and are subject to follow-up verification inspections.

What should families do?

Families should: (1) Ask facility administration about specific corrective actions taken, (2) Request to see the follow-up inspection report verifying corrections, (3) Check if this represents a pattern by reviewing prior inspection reports, (4) Compare this facility's ratings with other nursing homes in BRONX, NY, (5) Report any new concerns directly to state authorities.

Where can I see the full inspection report?

The complete inspection report is available on Medicare.gov's Care Compare website (www.medicare.gov/care-compare). You can also request a copy directly from NEW RIVERDALE REHAB AND NURSING or from the state Department of Health. The report includes specific deficiency codes, facility responses, and correction timelines. This facility's federal provider number is 335096.

Has this facility had violations before?

To check NEW RIVERDALE REHAB AND NURSING's history, visit Medicare.gov's Care Compare and review their inspection history, quality ratings, and staffing levels. Look for patterns of repeated violations, especially in critical areas like abuse prevention, medication management, infection control, and resident safety.